David Steffin, Interim Associate Director, Bone Marrow Transplant Program, Assistant Professor of Hematology/Oncology, Baylor College of Medicine, Texas Children’s Hospital
0:00 Big progress in pediatric cancers
6:22 How is spatial biology impacting immunotherapy?
10:57 What do various proximities by mapping tell you?
19:46 How do you decide on a marker?
13:53 How might this impact patient care soon?
David Steffin is a cancer researcher and physician at Texas Children's whose particular focus is on pediatric cancers. He begins today’s program with some interesting numbers.
The international community has made a lot of progress in childhood cancers over the past few years. In the ‘60s and ‘70s, the survival rate of pediatric leukemias was 5-10%. Now it’s greater than 90%, and higher in some subtypes. It’s not as good in solid tumor types, but still much better than it was, around 60 to 70%. David is focused on the hardest to fight—those solid tumor cancers with survival rates below 30%.
To go where no researcher has gone before, David is turning to the latest tools for help. Today he shares with us the impact of new spatial biology technology on his work, offering a close look “under the hood.”
How are the new high-resolution images of spatial technology leading him to new biomarkers? What does the so-called mapping of this new technology tell him—how does it help to know the proximity of certain exhausted T cells, for example, to certain parts of the tumor?
It’s an exciting time for researchers using this new technology. How is the spatial community developing and sharing their data and working together in real-time?
Thanks to Akoya Biosciences for sponsoring David's show and our first series on spatial biology.